Turn Therapeutics Inc. Common Stock (TTRX) is a publicly traded the market company. As of July 7, 2026, TTRX trades at $7.90 with a market cap of $212.09M and a P/E ratio of -63.88. TTRX moved +6.88% today. Year to date, TTRX is +107.28%; over the trailing twelve months it is flat. Its 52-week range spans $2.57 to $26.50. Rallies surfaces TTRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Turn Therapeutics Schedules Webcast on Interim Analysis and Optimized Stage 2 Design for GX-03: Turn Therapeutics will host a webcast presenting comprehensive interim analysis and optimized Stage 2 design for its GX-03 atopic dermatitis candidate. The live event will outline protocol refinements aimed at streamlining patient enrollment and sharpening clinical endpoints for the upcoming trial phase.
| Metric | Value |
|---|---|
| Price | $7.90 |
| Market Cap | $212.09M |
| P/E Ratio | -63.88 |
| EPS | $-0.12 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.50 |
| 52-Week Low | $2.57 |
| Volume | 91.37K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-3.19M |
| Gross Margin | 0.00% |
TTRX analyst coverage data. Average price target: $0.00.